Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cytarabine 166Cyclophosphamide 110Daunorubicin 88Methotrexate 83Etoposide 66Vincristine 63Mercaptopurine 55Rituximab 54Dexamethasone 54venetoclax 50fludarabine 47Doxorubicin 46Azacitidine 46Idarubicin 45Asparaginase 42Imatinib Mesylate 41Prednisone 39pegaspargase 37Thioguanine 36Radiotherapy 35Mitoxantrone 35Busulfan 31Peripheral Blood Stem Cell Transplantation 25Leucovorin 25Bendamustine Hydrochloride 25fludarabine phosphate 24Filgrastim 24obinutuzumab 23nilotinib 23Granulocyte Colony-Stimulating Factor 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Glutamic Acid × Other hematologic neoplasm × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡